Table of Contents
Precision Medicine Market Overview
Precision medicine, or personalized medicine, transforms healthcare by customizing treatment based on individual factors like genetics, environment, and lifestyle, diverging from the standard approach.
It utilizes genomics, sophisticated data analysis, and biomarkers to anticipate disease risks, aid in the diagnosis, and create tailored therapies.
With a focus on patient well-being and collaborative teamwork, precision medicine strives to enhance health results and boost patient contentment.
This approach shows great potential in refining treatment effectiveness and reducing negative impacts, paving the way for personalized healthcare advancements in the future.
Market Drivers
Advances in genomics and bioinformatics enhance disease diagnosis and treatment selection by pinpointing genetic variations.
Electronic health records (EHRs) and healthcare data analytics integrate patient data for personalized treatment plans.
Increased awareness among healthcare providers and patients about the advantages of precision medicine fuels the market growth. Government backing and investment in precision medicine research boost market expansion.
Collaborations among pharmaceutical firms, research institutions, and healthcare providers expedite the development and marketing of targeted therapies, driving global precision medicine adoption for improved patient outcomes and healthcare effectiveness.
Market Size
The projected size of the global precision medicine market is anticipated to reach approximately USD 254 billion by 2032, up from USD 83.4 billion in 2022, with a compound annual growth rate (CAGR) of 12.1% from 2022 to 2032.
List of Major Companies
These are the top ten companies operating in the Precision Medicine Market:
- Abbott
- Merck
- Illumina
- Thermo-Fisher-Scientific
- Bristol-Myers-Squibb
- Teva-Pharmaceuticals
- Hoffmann-La-Roche
- Pfizer
- Qiagen
- GE-Healthcare
Abbott
Company Overview
| Establishment Year | 1888 |
| Headquarter | Green Oaks, Illinois, U.S. |
| Key Management | Robert B. Ford (Chairman & CEO) |
| Revenue (US$ Bn) | $ 40.1 Billion (2023) |
| Headcount | ~ 114,000 (2023) |
| Website | http://abbott.com/ |
About Abbott Laboratories
Abbott Laboratories is making significant strides in precision medicine, introducing innovative products like the EnSite Precision™ Cardiac Mapping System for precise arrhythmia diagnosis and treatment.
Their CardioMEMS™ HF System enables remote heart failure patient monitoring, enhancing patient care. Through strategic acquisitions like CSI, Abbott strengthens its diagnostics and precision medicine offerings, particularly in cardiovascular care.
These efforts highlight Abbott’s dedication to utilizing advanced technology and data for personalized healthcare solutions, ultimately improving patient outcomes and advancing in the precision medicine market.
Geographical Presence
Abbott Laboratories, a major healthcare firm, has a broad global presence across 160+ countries, headquartered in Illinois, USA.
Operating extensively in North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East, Abbott caters to diverse healthcare needs worldwide.
With key hubs in the US, Canada, Europe (UK, Germany, France, Italy, Spain) and strategic locations in China, Japan, India, Australia, and South Korea, Abbott is committed to advancing healthcare innovation and improving global health outcomes through its extensive network of offices, manufacturing sites, and research centers.
Recent Developments
- In April 2024, Abbott’s Esprit™ BTK Everolimus Eluting Resorbable Scaffold System gained FDA approval, marking a breakthrough in treating chronic limb-threatening ischemia below the knee.
- In April 2024, Abbott revealed FDA approval for its groundbreaking TriClip™ transcatheter edge-to-edge repair (TEER) system, tailored for treating tricuspid regurgitation (TR), commonly known as a leaky tricuspid valve.
Merck
Company Overview
| Establishment Year | 1891 |
| Headquarter | Rahway, New Jersey, U.S. |
| Key Management | Robert M. Davis (Chairman, President and CEO) |
| Revenue (US$ Bn) | $ 60.1 B (2023) |
| Headcount | ~ 72,000 (2023) |
| Website | http://merck.com/ |
About Merck
Merck & Co., Inc. has significantly bolstered its presence in precision medicine through key acquisitions and product developments.
Notably, the company recently finalized the purchase of Prometheus Biosciences, a strategic move aimed at expanding its capabilities in immunology, particularly in treating inflammatory bowel diseases like ulcerative colitis and Crohn’s disease.
This $10.8 billion deal includes Prometheus’ groundbreaking PRA023, a monoclonal antibody. Merck also acquired Harpoon Therapeutics, enhancing its oncology portfolio with innovative T-cell engager therapies.
These acquisitions highlight Merck’s dedication to developing targeted treatments using advanced biomarker and precision medicine technologies, solidifying its position as a leader in personalized healthcare solutions.
Geographical Presence
Merck & Co., Inc., also known as Merck Sharp & Dohme (MSD) internationally, has a strong global presence based in Kenilworth, New Jersey.
Operating across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa, Merck strategically establishes offices, manufacturing sites, and research centers to serve diverse markets and promote healthcare innovation.
Collaborating with local partners, Merck addresses medical needs and enhances patient outcomes from the U.S. to emerging markets in Asia and Latin America.
Committed to advancing global health and pharmaceutical innovation, Merck utilizes its extensive network to drive progress in healthcare worldwide.
Recent Developments
- In March 2024, Merck completed its acquisition of Harpoon Therapeutics, Inc., turning it into a wholly-owned subsidiary.
- In April 2023, Merck, through a subsidiary, entered a definitive agreement to acquire Prometheus.
Illumina
Company Overview
| Establishment Year | 1998 |
| Headquarter | San Diego, California, U.S. |
| Key Management | Jacob Thaysen (CEO) |
| Revenue (US$ Bn) | $ 4.5 Billion (2023) |
| Headcount | ~ 9,250 (2023) |
| Website | http://illumina.com/ |
About Illumina
Illumina, Inc. leads in precision medicine, advancing through innovative technologies and partnerships. Recently, it unveiled PrimateAI-3D, an AI algorithm predicting disease-causing genetic mutations with unprecedented accuracy, using genetic data from 233 primate species.
This enhances clinical variant interpretation, improving genetic risk prediction and drug target discovery. Illumina’s collaborations, like with Bayer for the TruSight Oncology Comprehensive test, aid in identifying targeted therapies for cancer patients with NTRK fusion.
These initiatives highlight Illumina’s dedication to enhancing human health through precision medicine, offering advanced genomic analysis tools, and fostering global collaborations.
Geographical Presence
Illumina, headquartered in San Diego, California, has a strong global presence spanning North America, Europe, and the Asia-Pacific.
In North America, it operates in the United States and Canada, supporting research, development, and customer service.
In Europe, strategic offices in the UK, Germany, France, and Switzerland enhance its operations and collaborations.
Illumina also invests in the Asia-Pacific, including China, Japan, Australia, and Singapore, to meet the rising demand for genetic sequencing and analysis. This expansive reach underscores Illumina’s commitment to advancing genomic research worldwide.
Recent Development
- In April 2024, Illumina’s divestment plan for GRAIL gained approval from the European Commission (EC).
- In June 2023, Illumina unveiled PrimateAI-3D, an AI algorithm accurately predicting disease-causing genetic mutations in patients.
Thermo-Fisher-Scientific
Company Overview
| Establishment Year | 1958 |
| Headquarter | Waltham, Massachusetts, U.S. |
| Key Management | Marc N. Casper (CEO) |
| Revenue (US$ Bn) | $ 42.8 Billion (2023) |
| Headcount | ~ 122,000 (2023) |
| Website | http://www.thermofisher.com/ |
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. continues to lead in precision medicine with innovative solutions. Their Ion Torrent Genexus Dx Integrated Sequencer accelerates genomic profiling, delivering results within a day.
The Orbitrap Astral mass spectrometer revolutionizes proteomics, enhancing biomarker discovery and disease intervention.
Moreover, Thermo Fisher’s acquisition of Olink Holding AB strengthens its proteomics capabilities, advancing understanding of human biology for better patient outcomes.
These efforts underscore Thermo Fisher’s dedication to advancing precision medicine and enhancing global healthcare.
Geographical Presence
Thermo Fisher Scientific Inc. holds a prominent global presence, operating in over 150 countries across North America, Europe, Asia-Pacific, Latin America, and the Middle East.
With key hubs in the United States and Europe, the company strategically positions itself to serve diverse markets, including academia, pharmaceuticals, and industry.
Its extensive network of facilities and offices ensures the efficient delivery of advanced laboratory equipment and services to meet the evolving needs of the scientific community worldwide.
Thermo Fisher Scientific’s reach underscores its commitment to facilitating scientific innovation and research on a global scale.
Recent Development
- In October 2023, Thermo Fisher Scientific Inc. and Olink Holding AB both greenlit Thermo Fisher’s acquisition proposal for Olink.
- In June 2023, Thermo Fisher Scientific Inc. introduced the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, a groundbreaking advancement in mass spectrometry, marking a significant milestone in the field after 15 years.
Bristol-Myers-Squibb
Company Overview
| Establishment Year | 1887 |
| Headquarter | Princeton, New Jersey, U.S. |
| Key Management | Chris Boerner (CEO) |
| Revenue (US$ Bn) | $ 45.01 B (2023) |
| Headcount | ~ 34,100 (2023) |
| Website | http://bms.com/ |
About Bristol Myers Squibb
Bristol Myers Squibb is advancing precision medicine through strategic acquisitions and innovative launches.
Recently, FDA accelerated approval was granted for Breyanzi, a CAR T cell therapy targeting adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
This marks a significant stride in precision oncology, catering to patients with specific genetic profiles.
Additionally, Bristol Myers Squibb acquired Mirati Therapeutics for $4.8 billion, integrating the KRAS inhibitor adagrasib (Krazati) and other targeted oncology agents.
The company also partnered with Tempus in a research collaboration to employ multimodal AI to identify new drug targets and enhance cancer treatment options.
These actions underscore Bristol Myers Squibb’s commitment to advancing precision medicine through state-of-the-art technologies and strategic alliances.
Geographical Presence
Bristol Myers Squibb (BMS), a global biopharmaceutical company headquartered in New York City, boasts a widespread geographical presence across North America, Europe, and the Asia-Pacific region.
With key operations in the United States, Europe’s major markets, and prominent Asian countries like Japan and China, BMS strategically positions itself for commercial activities, research endeavors, and collaborations.
Additionally, the company extends its reach into Latin America, Africa, and the Middle East, albeit to varying extents.
This extensive global footprint underscores BMS’s dedication to delivering innovative therapies and enhancing patient care worldwide.
Recent Developments
- In March 2024, Bristol Myers Squibb revealed that the FDA had accelerated approval for Breyanzi, a CAR T cell therapy targeting CD19, for adult patients with relapsed or refractory CLL or SLL who have undergone at least two prior treatments, including a BTK inhibitor and a BCL-2 inhibitor.
- In November 2023, Tempus and Bristol Myers Squibb entered a multi-year strategic research partnership aimed at swiftly identifying and validating new targets in specific cancer areas using diverse datasets, computational methods, and patient-derived disease models.
Teva-Pharmaceuticals
Company Overview
| Establishment Year | 1901 |
| Headquarter | Tel Aviv, Israel |
| Key Management | Richard Francis (President and CEO) |
| Revenue (US$ Bn) | $ 15.8 Billion (2023) |
| Headcount | ~ 35,000 (2023) |
| Website | http://www.tevapharm.com/ |
About Teva Pharmaceuticals
Teva Pharmaceuticals is at the forefront of precision medicine, forging innovative partnerships and developing new products.
Recently, Teva joined forces with Sanofi to co-develop TEV’574, an anti-TL1A inhibitor aimed at treating ulcerative colitis and Crohn’s disease.
Valued at up to $1.5 billion, this collaboration underscores Teva’s dedication to advancing treatments for inflammatory bowel diseases.
Additionally, Teva has partnered with Closed Loop Medicine to integrate digital health tools with traditional therapies, advancing personalized medicine solutions.
These initiatives reflect Teva’s commitment to leveraging technology and strategic alliances to enhance its precision medicine offerings and improve patient outcomes.
Geographical Presence
Teva Pharmaceuticals boasts a global presence across North America, Europe, Asia, and Latin America. In North America, particularly in the United States and Canada, Teva’s distribution network and manufacturing facilities ensure widespread access to its generic and specialty medicines.
Europe represents another significant market for Teva, with strong footholds in key countries like Germany and the UK. In Asia, Teva addresses growing healthcare demands in markets such as Japan and China through strategic partnerships and tailored offerings.
Similarly, in Latin America, including Brazil and Mexico, Teva focuses on expanding access to affordable medications.
Overall, Teva’s extensive geographical reach underscores its commitment to providing quality healthcare solutions worldwide.
Recent Developments
- In March 2024, Teva UK Limited and Closed Loop Medicine Ltd formed a strategic partnership to advance personalized medicine development.
- In October 2023, Sanofi and Teva Pharmaceuticals partnered to develop jointly and market TEV’574, a TL1A inhibitor currently undergoing Phase IIb clinical trials for ulcerative colitis and Crohn’s disease, both forms of inflammatory bowel disease (IBD).
Hoffmann-La-Roche
Company Overview
| Establishment Year | 1896 |
| Headquarter | Basel, Switzerland |
| Key Management | Thomas Schinecker (CEO) |
| Revenue (US$ Bn) | $ 65.4 Billion (2022) |
| Headcount | ~ 122,000 (2022) |
| Website | http://www.roche.com/ |
About Roche
Roche is advancing precision medicine through strategic moves and partnerships. Recently, it acquired Foundation Medicine for $2.4 billion, boosting its personalized cancer diagnostics and therapies.
This acquisition integrates Foundation Medicine’s genomic profiling tech to develop targeted cancer treatments.
Roche also partnered with PathAI to enhance digital pathology using AI for better diagnostics. With ongoing innovations like the PI3Kα inhibitor inavolisib for breast cancer, Roche aims to offer more tailored treatment options, emphasizing its dedication to precision medicine.
Geographical Presence
Roche, a major player in pharmaceuticals and diagnostics, has a strong global presence spanning North America, Europe, Asia-Pacific, Latin America, and the Middle East/Africa.
In North America, the US and Canada are key centers for research, development, manufacturing, and commercial activities.
Europe, including Germany, Switzerland, France, and the UK, holds vital importance for Roche. The company is expanding in Asia-Pacific, targeting markets like China, Japan, India, and South Korea due to rising healthcare needs.
Latin America and the Middle East/Africa are also emerging markets for Roche, showcasing its commitment to enhancing healthcare outcomes worldwide through strategic investments.
Recent Developments
- In May 2024, Roche expanded its collaboration with Enable Injections to advance and utilize Enable’s expertise and enFuse delivery technology.
- In March 2024, Roche partnered with PathAI, a top AI technology provider in pathology, exclusively for developing AI-powered digital pathology algorithms in companion diagnostics.
Pfizer
Company Overview
| Establishment Year | 1849 |
| Headquarter | New York City, U.S. |
| Key Management | Albert Bourla (CEO) |
| Revenue (US$ Bn) | $ 58.5 Billion (2023) |
| Headcount | ~ 88,000 (2023) |
| Website | http://pfizer.com/ |
About Pfizer
Pfizer’s strategic acquisitions, such as the recent $43 billion purchase of Seagen, bolster its precision medicine capabilities, particularly in cancer therapeutics. This move enhances Pfizer’s oncology portfolio, allowing targeted cancer treatments to be delivered.
Additionally, Pfizer remains at the forefront of innovation with new product developments, including potential best-in-class inhibitors for breast and genitourinary cancers, showcased at the 2024 ASCO Annual Meeting.
These initiatives underscore Pfizer’s dedication to advancing personalized therapies through advanced technologies and strategic partnerships, ultimately aiming to improve patient outcomes.
Geographical Presence
Pfizer Inc. has a global presence across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa and is headquartered in New York City.
Its operations span from research and manufacturing in Europe to strategic investments in the rapidly growing Asia-Pacific region, particularly in China and Japan.
In Latin America, Pfizer partners to address healthcare disparities, while in the Middle East and Africa, it focuses on innovation in healthcare delivery. Overall, Pfizer is committed to improving patient outcomes and addressing global medical needs.
Recent Development
- In March 2024, Pfizer’s Prevenar 20 received approval from the European Commission to safeguard infants and children against pneumococcal disease.
- In February 2024, Pfizer partnered with UT Southwestern Medical Center to develop RNA-enhanced delivery technologies for genetic medicine therapies.
Qiagen
Company Overview
| Establishment Year | 1984 |
| Headquarter | Venlo, Netherlands |
| Key Management | Thierry Bernard (CEO) |
| Revenue (US$ Bn) | $ 1.9 Billion (2023) |
| Headcount | ~ 5,967 (2023) |
| Website | http://qiagen.com/ |
About Qiagen
Qiagen is advancing precision medicine with recent milestones, including FDA approval for a real-time PCR companion diagnostic for gastrointestinal tumors and launching the Therascreen EGFR Plus RGQ PCR Kit for non-small cell lung cancer.
These developments underscore Qiagen’s commitment to enhancing oncology diagnostics. Furthermore, Qiagen expanded its presence in the Middle East with a new headquarters in Riyadh, Saudi Arabia, and signed a memorandum of understanding with the Ministry of Health to support public health initiatives.
These strategic initiatives highlight Qiagen’s dedication to providing innovative diagnostic solutions globally.
Geographical Presence
Qiagen NV, a leader in sample and assay technologies for molecular diagnostics and research, maintains a strategic global presence across key regions.
With headquarters in Germantown, Maryland, USA, and a strong foothold in Europe, particularly in Germany, where it was founded, Qiagen serves diverse markets in North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East.
Leveraging local offices, manufacturing facilities, and distribution centers, Qiagen ensures proximity to major research hubs and customer bases, fostering innovation and meeting the evolving needs of the healthcare and life sciences industries worldwide.
Recent Developments
- In May 2024, Qiagen NV launched QCI Secondary Analysis.
- In April 2024, Qiagen NV introduced the QIAseq xHYB Mycobacterium Tuberculosis Panel.
GE-Healthcare
Company Overview
| Establishment Year | 1994 |
| Headquarter | Chicago, Illinois, U.S. |
| Key Management | Peter Arduini (CEO) |
| Revenue (US$ Bn) | $ 19.5 Billion (2023) |
| Headcount | ~ 51,000 (2023) |
| Website | http://gehealthcare.com/ |
About GE Healthcare
GE Healthcare is making significant strides in the precision medicine sector through various strategic initiatives and new product developments.
Recently, GE Healthcare launched the next-generation LOGIQ ultrasound portfolio, which offers enhanced imaging capabilities to support more precise diagnostics and treatment planning.
Additionally, the company has partnered strategically with MIM Software to enhance medical imaging analysis, further advancing its precision medicine capabilities.
Another notable development is the introduction of the CT-Navigation system, providing real-time 3D imaging for more accurate interventions in oncology and other medical procedures.
GE Healthcare’s collaboration with Minerva Imaging focuses on accelerating targeted radionuclide therapies, aiming to bring innovative cancer treatments to the market more quickly.
These efforts demonstrate GE Healthcare’s commitment to integrating advanced technologies and strategic partnerships to improve patient outcomes in precision medicine.
Geographical Presence
GE Healthcare boasts a significant global presence, operating across North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East.
In North America, it delivers innovative solutions to healthcare providers, while in Europe, it maintains a strong foothold through offices, manufacturing sites, and research facilities.
GE Healthcare aligns its offerings with diverse healthcare systems ‘ needs across the Asia-Pacific region, including key markets like China and India.
Additionally, it extends its reach to Latin America, Africa, and the Middle East, aiming to enhance healthcare accessibility and quality in these regions.
Overall, GE Healthcare’s widespread geographical presence underscores its commitment to advancing healthcare worldwide.
Recent Developments
- In May 2024, GE Healthcare collaborated with Medis Medical Imaging to advance precision care in diagnosing and treating coronary artery disease.
- In February 2024, GE Healthcare and Biofourmis united to improve care continuity via safe, effective, and accessible home-based services, extending support beyond hospitals. This collaboration maximizes their expertise to scale and deliver innovative home care solutions.
Discuss Your Needs With Our Analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
